|
|
|
|
|
| First Name: | Albrecht | | Last Name: | Stöffler | | Title: | Dr. | | Advanced Degrees: | MD | | Affiliation: | Independent Consultant | Country/Territory: | Germany | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports the following financial or other potential conflicts of interest: [Last Modified: 5 July 2009]
I was an employee of:
Merz Pharmaceuticals, Germany (1997 to 2006) and
AstraZeneca Clin. Neuroscience, Sweden (November 2007 to March 2009).
Currently I act as a consultant for various pharmaceutical companies.
|
|
|
View all comments by Albrecht Stöffler
|
Tauopathies, Parkinson Disease, Prion Diseases, Alzheimer Disease, Aging Process
|
Neurobiology, Clinical trials, Diagnosis, Translational Medicine
|
Albrecht Stoeffler was born in Besigheim/Neckar, Germany. He graduated at the University of Heidelberg in 1979 as M.D. with a thesis on anorexia nervosa. As a board certified neurologist and psychiatrist he worked in a variety of clinical settings from neurological intensive care units to outpatient psychotherapy.
He now works as an independent consultant mainly for Alzheimer-related topics.
1997-2006 he was Director of Clinical Research & Development CNS at Merz Pharmaceuticals in Frankfurt/Main (Germany).
Until March 2009 he had a position as Disease Area Medical Leader for Neurology/Alzheimer's Disease at AstraZeneca Clinical Neuroscience in Södertälje (Sweden) |
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, and Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348(14): 1333-41.
PMID: 12672860 [PubMed - indexed for MEDLINE]
Free article in PMC | at journal site
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, and Möbius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63(1):49-54.
PMID: 16401736 [PubMed - indexed for MEDLINE]
Free article in PMC | at journal site
Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, and Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia; a randomized, placebo-controlled trial (MMM300). Stroke 2002; 33:1834-1839.
PMID: 16401736 [PubMed - indexed for MEDLINE]
Free article in PMC | at journal site
Wilcock G, Stöffler A, and Möbius HJ. A double-blind, placebo-controlled multicenter study of memantine in mild to moderate vascular dementia (the MMM500 trial). International Clinical Psychopharmacology 2002;17(6):297-305.
PMID: 12409683 [PubMed - indexed for MEDLINE]
Parsons CG, Stöffler A, and Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 10-8-2007; 53:699-723.
PMID: 17904591 [PubMed - indexed for MEDLINE]
Winblad B, Jones RW, Wirth Y, Stöffler A, and Möbius HJ. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24[1]:20-27.
PMID: 17496417 [PubMed - indexed for MEDLINE]
Möbius HJ and Stöffler A. New approaches to clinical trials in vascular dementia: Memantine in small vessel disease. Cerebrovasc Dis 2002; 13[Suppl. 2]:61-66.
PMID: 11901246 [PubMed - indexed for MEDLINE] |
|
|
|
|
|
|
Home
